- Location
radiopharmaceutical
"-
FDA Has Approved Navidea Biopharmaceuticals' Lymphoseek Injection
Mar 15, 2013The US Food and Drug Administration (FDA) has approved Navidea Biopharmaceuticals' Lymphoseek (technetium Tc 99m tilmanocept) injection, a novel product indicated for use in lymphatic mapping procedure. The lymphatic mapping procedure ...
Tags: FDA, Biopharmaceuticals, Navidea Biopharma
-
Navidea Has Jouned Forces with Maimonides Medical Centre Investigate Lymphoseek
Feb 6, 2013Navidea Biopharmaceuticals has jouned forces with Maimonides Medical Centre to investigate Lymphoseek injections as a potential treatment for colorectal cancer. Dr. Danny Sherwinter, surgeon and the director of the Department of Minimally ...
-
Eli Lilly and Company and Avid Radiopharmaceuticals Announced The Approval of Amyvid
Jan 17, 2013Eli Lilly and Company and Avid Radiopharmaceuticals have announced the approval of Amyvid (Florbetapir (18F)) solution for injection in European Union to detect the beta-amyloid neuritic plaque density in patients with cognitive impairment ...
Tags: diagnostic radiopharmaceutical, Eli Lilly Amyvid, disease
-
License, Distribution Agreement with FRI for Radiopharmaceuticals Is Renewed by Lantheus
Jan 5, 2013Lantheus Medical Imaging has renewed its long-term agreement with FUJIFILM RI Pharma (FRI) to license and distribute its technetium-based radiopharmaceutical imaging agents, used in single-photon emission computed tomography (SPECT), in ...
Tags: Lantheus Medical Imaging, FUJIFILM, Radiopharmaceuticals
-
Navidea Has Entered Into an Agreement to License Alseres Parkinson's Disease Imaging Agent
Dec 18, 2012Navidea Biopharmaceuticals has entered into an agreement to license Alseres Pharmaceuticals' Iodine-123 radiolabeled imaging agent, [123I]-E-IACFT Injection (CFT). The patented small molecule radiopharmaceutical imaging agent, which ...
-
Navidea Biopharmaceuticals Reported Net Loss Attributable to Common Stockholders of$9.12m
Dec 4, 2012Navidea Biopharmaceuticals has reported a net loss attributable to common stockholders of $9.12m, or $0.09 per share, for the third quarter ended 30 September 2012 compared to a net income attributable to common stockholders of $19.81m, or ...
Tags: Navidea Biopharmaceuticals, common stockholders, radiopharmaceutical
